TEM
Tempus AI Inc
$58.36
▲ 18.2%Updated Today 11:10 AM ET
TEM at a glance — five pillars scored 0–100 from real filed financials.
Overall: Unrated · 0/100. A wider, greener shape means more pillars look healthy. Dividends scores 0 when a company pays none — that is a choice, not a flaw.
Market Cap
$0.00
P/E
—
Forward P/E (est.)
—
ROE
—
Revenue Growth
—
EPS Growth
—
Profit Margin
—
FCF Yield
—
Debt / Equity
—
ROIC
-45.0%
Interest Coverage
—
Current Ratio
3.3x
Dividend Yield
—
Implied Growth (rev. DCF)
—
Rating Score
0/100
Tempus AI Inc (TEM) is a small-cap company in the Life Sciences Tools & Services industry, part of the Health Care sector of the S&P 500.
In its latest reported year it generated about $1.27B in revenue and posted a net loss of $245.03M.
Our model rates TEM Unrated (0/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
3Y CAGR
58.3%
Revenue moved from $320.67M in 2022 to $1.27B in 2025, a 58.3% compound annual growth rate. The most recent year was roughly steady year over year. Slower, mature growth is common for established businesses.
Gross Margin
—
Operating Margin
-19.9%
Net Margin
-19.3%
ROE
—
Total Debt
—
Net Debt
—
Net Debt / EBITDA
—
Debt / Equity
—
Leverage: debt-to-equity is n/a, with a current ratio of 3.3x. Detailed balance-sheet leverage is limited for this name.
Operating CF
-$218.09M
Free Cash Flow
-$239.14M
FCF Margin
-18.8%
In the latest year Tempus AI Inc produced about -$218.09M of operating cash flow but negative free cash flow as it invested heavily. Cash flow is what ultimately pays shareholders, so it is worth tracking over time.
Can the payout survive a bad year? Scored from filed cash flow, earnings coverage, and the raise/cut record.
Coverage is weak, the payout was cut recently, or it's being financed rather than earned — treat the current yield as fragile.
Total paid (latest FY)
$5.63M
History on record
3 years
free cash flow was negative in the latest year — the dividend is being financed
no current raise streak
no cuts in the last 3 years on record
Coverage uses the latest fiscal year as filed with the SEC; the streak counts total dollars paid (per-share figures can carry split artifacts). Educational information, not income advice.
P/E
—
P/S
—
P/B
—
EV / EBITDA
—
TEM trades at n/a trailing earnings. With no positive trailing earnings, value it on sales, cash flow, or growth rather than P/E.
Where TEM sits versus its Health Care sector peers in the S&P 500.
Bands show the middle half (25th–75th percentile) of the 83 Health Care companies in the S&P 500 — the peer-relative anchor professional comps analysis uses. Context only — not investment advice.
How TEM stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
In the Health Care sector (324 S&P 500 companies), TEM ranks #297 of 324 by our overall rating.
P/E vs sector
—
median 27.3x
ROE vs sector
—
median 14.1%
Growth vs sector
—
median 7.6%
Sector rank
#297
of 324 by rating
Peers are the closest Health Care companies by sub-industry and size. Sector median is across all 324 S&P 500 names in the sector. Educational, not a recommendation.
The case for TEM:
- As an established S&P 500 member in Health Care, it brings scale and a long operating history.
The case against TEM:
- Like any single stock, it is exposed to competition, the economic cycle, and shifts in its end markets.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the picture is mixed: Tempus AI Inc is a small-cap health care business growing at a mature pace, with modest profitability, and a heavier debt load to watch. It trades at n/a earnings, which our model scores Unrated (0/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Latest SEC Filings
TEM's most recent filings, straight from SEC EDGAR. Annual and quarterly reports are the deep dives; 8-Ks flag material events the moment they happen.
TEM — frequently asked questions
Is TEM a good stock to buy?
We don't give buy or sell advice. Review Tempus AI Inc's fundamentals, valuation, and 5-year financials on this page, then make your own decision — and consider a licensed professional.
Where does TEM's data come from?
Live price data plus real fundamentals and 5-year financials pulled directly from Tempus AI Inc's SEC filings — refreshed automatically, not hand-entered.
How is the 5-year projection for TEM calculated?
It's a scenario model: it grows revenue at an assumed rate, applies a profit margin and a valuation multiple, and shows the resulting share-price range. The assumptions are yours to change — it's a tool for thinking, not a prediction.
Is this TEM analysis financial advice?
No. Everything on this page is educational research, not financial advice or a recommendation to buy or sell TEM. Always do your own research and consider a licensed professional.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.